Lightnews — Scholar-powered news

Megen Wittling @megen-w.bsky.social · 14d

Check out our new research on developing a model for tumor infiltrating lymphocyte (TIL) therapy for cholangiocarcinoma (CCA) by the Lesinski and Paulos Labs!
@lesinskilab.bsky.social
@chrystalpaulos.bsky.social

academic.oup.com/jimmunol/adv...

Development of a murine tumor-infiltrating lymphocyte therapy model for cholangiocarcinoma

Abstract. Tumor-infiltrating lymphocyte (TIL) therapy is a promising approach, earning U.S. Food and Drug Administration approval in patients with anti–PD-

academic.oup.com

1 3

Reposted by Megen Wittling

Society for Immunotherapy of Cancer @sitcancer.bsky.social · Sep 4

New Journal for ImmunoTherapy of Cancer position article and guidelines: Constructing the cure: engineering the next wave of antibody and cellular immune therapies bit.ly/3HYCbrs

#JITC #ImmunoSky #MedSky

Constructing the cure: engineering the next wave of antibody and cellular immune therapies

Immuno-oncology has revolutionized cancer treatment by mobilizing the immune system to eliminate tumors. Although immune checkpoint inhibitors and T cell therapies have mediated durable responses in h...

bit.ly

2 6

Reposted by Megen Wittling

Chrystal Paulos @chrystalpaulos.bsky.social · Jul 25

🧵1/ New in @Cancer_Cell: Our lab discovered that Th17 cells must team up with B cells to eliminate tumors, and prevent it from coming back.
🔗 Read: www.cell.com/cancer-cell/...
🧬This unexpected immune duo sparks tumor immunity.
🖼️Image: See schematic Th17/B cell antitumor action!

Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity

Cole et al. report that adoptively transferred, tumor-specific Th17 cells engage host B cells and drive B cell proliferation and differentiation. These Th17 cells require B cells for sustained immunit...

www.cell.com

1 13 29

Reposted by Megen Wittling

LesinskiLab @lesinskilab.bsky.social · Jul 3

Check out our new paper in Hepatology on how myeloid cells limit immunotherapy in preclinical cholangiocarcinoma models!
Disease site matters! @chrystalpaulos.bsky.social @megen-w.bsky.social @winshipcancer.emory.edu many others!

pubmed.ncbi.nlm.nih.gov/40590857/

Tumor site influences efficacy of MEKi and immunotherapy combinations in pre-clinical model of cholangiocarcinoma - PubMed

These findings identify myeloid cells as key mediators of both immunotherapy resistance and toxicity in CCA, highlighting the critical importance of tumor site and use of physiologically relevant pre-...

pubmed.ncbi.nlm.nih.gov

1 3 7

Reposted by Megen Wittling

Chrystal Paulos @chrystalpaulos.bsky.social · Apr 25

Our findings highlight the critical role of T cell trafficking to the lymph nodes in shaping neoantigen-specific antitumor responses and offers insight for improving adoptive cellular therapies www.biorxiv.org/content/10.1...

Neoantigens drive adoptively transferred CD8 T cells to long-lived effectors mediated by lymph node trafficking

Adoptive transfer of neoantigen-reactive T lymphocytes mediates potent responses against solid tumors in patients while often limiting toxicity to normal tissues; however, the mechanisms governing the...

www.biorxiv.org

2 2

Reposted by Megen Wittling

LesinskiLab @lesinskilab.bsky.social · Apr 12

Inspiring (as always) @cholangiocarcinoma.bsky.social annual meeting comes to a close. Our @winshipatemory.bsky.social team returns motivated by survivors, patients and caregivers to make a difference! @megen-w.bsky.social @chrystalpaulos.bsky.social

4 6

Reposted by Megen Wittling

Chrystal Paulos @chrystalpaulos.bsky.social · Mar 27

💥Cheers to Megen Wittling @megen-w.bsky.social @winshipatemory.bsky.social for presenting exciting work on the distinct trafficking & activation patterns of adoptively transferred CD8 T cells that recognize non-mutated va mutated tumors.

1 3

Megen Wittling @megen-w.bsky.social · Feb 19

Thank you!!

1

Reposted by Megen Wittling

Chrystal Paulos @chrystalpaulos.bsky.social · Feb 19

Congrats to our talented grad student Megen Wittling for being award this NCI F30 grant for her work in adoptive immunotherapy today! @megen-w.bsky.social @winshipatemory.bsky.social @sitcancer.bsky.social #EmoryMSTP

1 7

Reposted by Megen Wittling

Winship Cancer Institute of Emory University @winshipcancer.emory.edu · Feb 10

🎉Congrats to Emory cancer immunologist Chrystal Paulos, PhD, (@chrystalpaulos.bsky.social) who has been named co-leader of the Cancer Immunology Research Program at Winship. ➡️ brnw.ch/21wQB3h

1 11

Reposted by Megen Wittling

Chrystal Paulos @chrystalpaulos.bsky.social · Jan 28

Cheers to @megen-w.bsky.social and #HeatherLin in the CB program @winshipatemory.bsky.social for brilliant talks on adoptive immunotherapy in yesterdays seminar series.

1 2